Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.
暂无分享,去创建一个
B. Hendriks | G. Sahagian | W. Kamoun | W. Muller | N. Dumont | D. Drummond | T. Wickham | V. Papavasiliou | E. Geretti | L. Luus | O. Ghasemi | C. Espelin | Samantha Merrigan | Jason Turpin | C. Lavoie
[1] J. Lancet,et al. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. , 2018, Future oncology.
[2] Karen Campbell,et al. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[3] K. Strasser-Weippl,et al. Current and emerging therapies of HER2-positive metastatic breast cancer. , 2016, Breast.
[4] S. Alzghari,et al. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[5] O. Griffith,et al. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment , 2016, Oncogene.
[6] Yan-Shen Shan,et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.
[7] Meiyuan Xing,et al. Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials , 2015, PloS one.
[8] C. Desmedt,et al. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Maeda,et al. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls , 2015, Expert opinion on drug delivery.
[10] M. Campiglio,et al. Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. , 2014, Cancer research.
[11] Ana C. Gregório,et al. Bridging cancer biology and the patients' needs with nanotechnology-based approaches. , 2014, Cancer treatment reviews.
[12] C. Hudis,et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. , 2014 .
[13] Seiji Miura,et al. Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[14] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[15] N. Aceto,et al. Mammary tumor formation and metastasis evoked by a HER2 splice variant. , 2013, Cancer research.
[16] R. Kerbel,et al. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. , 2013, Breast.
[17] U. Nielsen,et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. , 2012, Toxicology and applied pharmacology.
[18] P. Sonneveld,et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] F. Muggia,et al. Phase III data on Caelyx in ovarian cancer. , 2001, European journal of cancer.
[21] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[22] R. Cardiff,et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.
[23] M. Hung,et al. A novel splice variant of HER2 with increased transformation activity , 1998, Molecular carcinogenesis.
[24] M A Fischl,et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Farthing,et al. Lactobacilli to prevent traveler's diarrhea? , 1995, The New England journal of medicine.
[26] J. Silber,et al. Doxorubicin-induced cardiotoxicity. , 1995, The New England journal of medicine.
[27] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.